Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma

被引：2
|
作者：
Jetsrisuparb, A [1 ]
Wiangnon, S
Komvilaisak, P
Kularbkaew, C
Yutanawiboonchai, W
Mairieng, E
机构：
[1] Khon Kaen Univ, Fac Med, Dept Pediat, Khon Kaen 40002, Thailand
[2] Khon Kaen Univ, Fac Med, Dept Pathol, Khon Kaen 40002, Thailand
[3] Khon Kaen Univ, Fac Med, Dept Radiol, Khon Kaen 40002, Thailand
来源：
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2005年 / 27卷 / 04期
关键词：
rituximab; aggressive recurrent non-Hodgkin's lymphoma; pediatric patient; anti-CD20 monoclonal antibody; CD20-positive B-cell large cell non-Hodgkin's lymphoma;
D O I：
10.1097/01.mph.0000158089.92165.a8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This report is the first to describe the successful treatment of a 14-year-old boy with aggressive recurrent, CD20-positive, B-cell large cell non-Hodgkin's lymphoma. The patient responded to three 4-week courses of rituximab (MabThera) given every 6 months and six cycles of CHOP given every 3 weeks in addition to a modified BFM 86 protocol. Transient neutropenia and lymphopenia occurred but with no clinical significance. The boy has been disease-free for the last 48 months (after 64 months of follow-up); his organ functions are normal. Rituximab and CHOP in addition to chemotherapy may be an alternative treatment for aggressive recurrent, pediatric CD20-positive B-cell large cell non-Hodgkin's lymphoma if highly intensive chemotherapy and stem cell transplantation are not available.
引用
收藏
页码：223 / 226
页数：4
相关论文
共 50 条
  • [1] Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma
    David Aguiar Bujanda
    José Aguiar Morales
    Uriel Bohn Sarmiento
    Salvador Saura Grau
    Carlos Rodríguez Franco
    Clinical and Translational Oncology, 2009, 11 : 604 - 608
  • [2] Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma
    Aguiar Bujanda, David
    Aguiar Morales, Jose
    Bohn Sarmiento, Uriel
    Saura Grau, Salvador
    Rodriguez Franco, Carlos
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (09) : 604 - 608
  • [3] Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma
    Simon, Zs.
    Tarr, T.
    Ress, Zs.
    Gergely, L.
    Kiss, E.
    Illes, A.
    RHEUMATOLOGY INTERNATIONAL, 2007, 28 (02) : 179 - 183
  • [4] Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma
    Zs. Simon
    T. Tarr
    Zs. Ress
    L. Gergely
    E. Kiss
    A. Illes
    Rheumatology International, 2007, 28 : 179 - 183
  • [5] Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma
    Blasco, Helene
    Chatelut, Etienne
    de Bretagne, Isabelle Benz
    Congy-Jolivet, Nicolas
    Le Guellec, Chantal
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 (05) : 601 - 608
  • [6] Rituximab in B-cell disorders other than non-Hodgkin's lymphoma
    Bosly, A
    Keating, MJ
    Stasi, R
    Bradstock, K
    ANTI-CANCER DRUGS, 2002, 13 : S25 - S33
  • [7] Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin's lymphoma in a developing country?
    Ruiz-Delgado, Guillermo J.
    Gomez-Almaguer, David
    Tarin-Arzaga, Luz C.
    Cantu-Rodriguez, Olga G.
    Alarcon Urdaneta, Carlos
    Rodriguez-Morales, Uxmal
    Calderon-Garcia, Jackeline
    Fernandez-Vargas, Omar
    Montes-Montiel, Maryel
    Sanchez-Cardenas, Nica
    Ruiz-Argueelles, Guillermo J.
    HEMATOLOGY, 2012, 17 (04) : 193 - 197
  • [8] Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the UK
    Sweetenham, J
    Hieke, K
    Kerrigan, M
    Howard, P
    Smartt, PFM
    McIntyre, AM
    Townshend, S
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (01) : 47 - 54
  • [9] Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness
    Badin, Firas
    Hayslip, John
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2010, 2 : 37 - 45
  • [10] Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
    Sacchi, S
    Federico, M
    Dastoli, G
    Fiorani, C
    Vinci, G
    Clò, V
    Casolari, B
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 37 (01) : 13 - 25
12345